MIPOMERSEN: A NOVEL THERAPEUTIC DRUG FOR THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA, HYPERLIPIDAEMIA, AND HYPERCHOLESTEROLEMIA
Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2016, Vol 8, Issue 3
Abstract
Familial Hypercholesterolemia (FH) is one of the most common autosomal dominant disorders which exist in either heterozygous form or a homozygous form. These two forms are prevalent in1 in500 and1 ina million population respectively. FH results in premature atherosclerosis; as early as childhood in case of homozygous (HoFH) form and in adults in case of heterozygous (HeFH) form. In case of HoFH both the alleles forLDL-receptor are defective, whereas the mutation in the single allele is the cause for HeFH. Both the forms of the disease are associated with high levels ofLDL-C and lipoprotein (a) in plasma, with high morbidity and mortality rate caused by cardiovascular disease. In several past years, different lipid-lowering drugs like Statins (HMG-coenzyme-A reductase inhibitor), MTTP inhibitor, CETP inhibitors, PCSK9 inhibitor, thyroid mimetics, niacin, bile acid sequestrants and lipid apheresis were administered to patients with FH, to achieve the goal of reducing plasmaLDL-C and lipoprotein (a). However, such drugs proved inefficient to achieve the goals because of several reasons. Mipomersen is a 20 nucleotide antisense oligonucleotide; a novel lipid-lowering therapeutic drug currently enrolled in the treatment of patients with HoFH, HeFH and other forms of hypercholesterolemia. It arrests the synthesis of Apo B100 by targeting Apo B100 mRNA and thus inhibiting the synthesis and release of all Apo B-containing lipoproteins, such as very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low-density lipoprotein (LDL), and non-high-density lipoprotein. It also lowers lipoprotein (a), and ultimately reduces the severity of coronary artery disease and cardiovascular disease.Keywords: Hypercholesterolemia, Low-density lipoprotein, Mipomersen, Cholesterol, Lipoprotein, Antisense oligonucleotideÂ
Authors and Affiliations
Ajay Kumar, Arun Acharya, Dinobandhu Nandi, Neha Sharma, Ekta Chitkara
Keywords
Related Articles
- EP ID EP577760
- DOI -
- Views 52
- Downloads 0
APPLICATION OFF-LINE SPE-HPLC/UV METHODS IN ANALYSIS OF OFLOXACIN IN HUMAN URINE (IN VITRO)
Objective: The objective of this study is to determine the validity of analytical methods in OFX antibiotic study in human urine (in vitro) using an SPE-HPLC/UV. In this study, SPE was applied in preparing the analysis o...
PROTECTING OUTCOME OF ETHYL ACETATE FRACTION OF AQUEOUS-METHANOL: 40:60 EXTRACT OF SEED OF MYRISTICA FRAGRANS HOUTT. IN STREPTOZOTOCIN-INDUCED DIABETIC RAT: A DOSE DEPENDENT STUDY
Objective: The investigation has been conducted to find out the threshold dose of ethyl acetate fraction prepared from aqueous-methanol (40:60) extract of seed of Myristica fragrans (Houtt.) from the dose dependent exper...
IN VITRO ANTIOXIDANT ACTIVITIES FROM VARIOUS EXTRACTS OF BANANA PEELS USING ABTS, DPPH ASSAYS AND CORRELATION WITH PHENOLIC, FLAVONOID, CAROTENOID CONTENT
Objectives: The objectives of this research were to study antioxidant capacity from various extracts of banana peels using two methods of antioxidant testing which were ABTS (2.2’-azino-bis (3-ethylbenzthiazoline-6-sul...
SOLUBILITY ENHANCEMENT OF KETOCONAZOLE VIA SALT AND COCRYSTAL FORMATION
Objective: Pharmaceutical salt and cocrystal is a promising alternative method for improving the solubility and dissolution rate of active pharmaceutical ingredients. In this work, an attempt was made to improve solubili...
IN SILICO MODELLING OF β-LACTAM RESISTANT ENTEROCOCCUS FAECALIS PBP4 AND ITS INTERACTIONS WITH VARIOUS PHYTO-LIGANDS
Objective: The resistance to β-lactam antibiotics is a serious problem worldwide. This resistance has emerged due to two main mechanisms: production of β-lactamases that hydrolyses β-lactam antibiotics and other is th...